Drug Profile
Fulvestrant - AstraZeneca
Alternative Names: Faslodex; ICI 182780; ZD 182780; ZD 9238; ZM 182780Latest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Baylor Research Institute; Celcuity; Eli Lilly and Company; Novartis; Pfizer; Seagen
- Class Antineoplastics; Estradiol congeners; Estrenes; Fluorinated hydrocarbons; Small molecules; Sulfoxides
- Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Precocious puberty
- No development reported Endometrial cancer
- Discontinued Endometriosis
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 05 Dec 2023 Updated adverse events data from a phase III CAPItello-291 trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 20 Oct 2023 Efficacy and adverse events data from the phase III FALCON trial in Breast cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)